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Abstract: The Spanish registry of alpha-1 antitrypsin deﬁ  ciency was founded in 1993 and 
became a member of the International Registry (AIR) in 1999. We describe the updating 
process following its incorporation into AIR and compare the data collected in the ﬁ  rst period 
(1993–1999) and the second period (1999–2005), during which time patients were included 
exclusively by internet.
The registry included 301 patients during period 1, 69% males and 46% had a history of 
smoking. Their mean age was 46 years (SD = 13) and 284 (94%) had the ZZ phenotype, 49% 
received augmentation therapy. During period 2, 161 new cases were included, 63% of whom 
were males with a mean age of 44 years (SD = 16). A total of 126 (78%) had the ZZ phenotype. 
Only 12% received augmentation therapy. A total of 462 different patients were included in both 
periods. Signiﬁ  cant differences were observed in the number of cases with the SZ phenotype 
and the severity of FEV1 impairment between the two periods.
Implementation of an internet-based collection of data did not result in a lower rate of 
reporting to the registry. However, data from a signiﬁ  cant number of patient included in period 
1 could not be actualized in the new data base.
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Introduction
Alpha-1 antitrypsin deﬁ  ciency (AAT) is a hereditary recessive autosomal disease 
caused by mutations in the AAT gene. This disease is characterized by abnormally 
low AAT concentrations in plasma, which, in its homozygote form, carries a high risk 
of the development of early pulmonary emphysema and, occasionally, liver damage 
(Carrel et al 1996; Eriksson 1996).
Recent studies in Spain have shown that 1.5% of the general population has the 
Z allele, thus, of a population of approximately 40 million, 8,000 individuals may be 
expected to have severe homozygotic PiZZ deﬁ  ciency (Blanco et al 2006).
Since the end of the 1980s, augmentation therapy with AAT from human plasma 
has been available for speciﬁ  c treatment of emphysema due to AAT deﬁ  ciency 
(Mastrangeli and Crystal1996). The need for consensus criteria for treatment and follow 
up led to the creation of the Spanish registry of patients with AAT deﬁ  ciency in 1993, 
within the working area of respiratory insufﬁ  ciency and sleep disorders (IRTS) of the 
Spanish Society of Pneumology and Thoracic Surgery (SEPAR) (Vidal et al 1995).
The registry also provides advice on aspects related to the diagnosis, the treatment 
and the follow up of patients with AAT deﬁ  ciency and participates in international 
investigation projects (Vidal et al 1996; Miravitlles et al 1998, 1999).
The low prevalence of AAT deﬁ  ciency makes the creation of international registries 
necessary as suggested by the World Health Organization (WHO) in its information 
bulletin in 1997 (WHO 1997). Only in this way can a large enough population of 
patients be gathered to perform clinical studies aimed at determining the efﬁ  cacy of International Journal of COPD 2007:2(3) 394
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new treatments for this disease. Following these guidelines, 
in 1999 the Spanish registry became a member of the alpha-1 
international registry (AIR) which is currently made up of 
the association of 21 national registries from four continents 
(Luisetti et al 2002).
The structure of the Spanish registry has undergone dif-
ferent changes during the 13 years of its activity. The most 
important change was the implementation of a new data col-
lection system through the internet over an ofﬁ  cial SEPAR 
website (http://www.separ.es/air) in 2001. This change was 
accompanied by modiﬁ  cations in the questionnaire in order 
to adapt it to the format of the AIR questionnaire translated 
into Spanish. In many cases this change in methodology 
made the updating of data necessary. This study describes 
this updating process and compares the data reported in the 
patients included during the ﬁ  rst period (1993–1999) with 
those obtained during the second period (1999–2005).
Methods
We carried out a descriptive study of the characteristics of the 
patients with AAT deﬁ  ciency included in the Spanish registry 
during the two periods of activity, period 1 (1993–1999) and 
period 2 (1999–2005).
The criteria for inclusion in the registry is the presence 
of severe AAT deﬁ  ciency deﬁ  ned by AAT plasma concen-
trations less than 30% of the normal value. In addition, the 
patients must be carriers of a PiZZ, PiSZ or some other severe 
phenotypic variant of the deﬁ  ciency. The criteria for inclusion 
in the registry have changed: in period 1 only patients over 
18 years with a PiZZ phenotype, null or severe deﬁ  ciency 
were included while, according to the AIR inclusion criteria, 
there was no age limit and PiSZ heterozygotes were also 
accepted in period 2.
During period 1 the information was collected on paper 
forms sent by post to the SEPAR headquarters to be thereafter 
distributed to the coordinators who updated the database. 
A questionnaire was developed in period 2 based on the 
questionnaire of the AIR registry translated into Spanish 
and was available in the HTML format and was linked to 
an Oracle database. The questionnaire is accessible through 
the SEPAR website (http://www.separ.es/air). The data of 
the registry were collected following the prevailing legisla-
tion on the conﬁ  dentiality of personal data. The database of 
the registry has been declared to the Spanish agency of data 
protection. The registry page is of restricted access and each 
participating physician must ﬁ  rst be registered and obtain a 
user name and password. The candidates to be registered are 
manually identiﬁ  ed as physicians by those responsible for the 
registry prior to authorization of access. Data conﬁ  dentiality 
is ensured by identifying each patient with a 3 digit number 
and the name of the corresponding physician, thus, each 
physician only has access to the data of his/her own patients 
and is only able to identify his/her patients.
The new questionnaire includes demographic data, smok-
ing history, respiratory symptoms, phenotype and reasons 
for AAT determination. It also collects data on respiratory 
function (FVC and FEV1 pre- and post-bronchodilator, CV 
and DLCO) and quality of life according to the score of the 
St. George’s respiratory questionnaire. Other questions refer 
to augmentation therapy, associated diseases, and lung and 
liver transplantation. One speciﬁ  c section is designed to regis-
ter data on clinical and functional evolution each semester.
The information collected in the new questionnaire was, 
in part, different and more extensive than that reported dur-
ing the ﬁ  rst period, thereby requiring progressive updating 
by direct contact with the physicians who registered the 
patients in period 1 and who did not have patients registered 
in period 2. On compiling the maximum data possible, a 
comparative analysis was made between the patients from 
periods 1 and 2 to determine the common variables in the 
questionnaires used in the two periods.
Statistical analysis
The baseline characteristics of the patients included in periods 
1 and 2 are presented. Patients included in period 1 were 
divided into updated and not updated according to whether 
they had been newly registered in period 2 through the on-line 
database. The comparisons betweens the two groups were 
performed with the Chi-square test for qualitative variables 
and the Student’s-t test for quantitative variables, with 
p < 0.05 being considered signiﬁ  cant.
Results
A total of 301 individuals were registered in period 1, 69% of 
whom were males with a mean age of 46 years (SD = 13 years) 
and 46% had a history of smoking (Table1). The ZZ phenotype 
was reported in 284 patients (94%) and 49% had received 
augmentation therapy at some time during their evolution.
In period 2, 161 new cases were included (Table 1). Of 
these 63% were males with a mean age of 44 years (SD  
=  16 years). Ten individuals were younger than 18 years, 
7 boys and 3 girls with a mean age of 12 years (range: 2 
to 17 years). A total of 126 had the ZZ phenotype while 
the remaining patients were of the PiSZ phenotype. Only 
12% received augmentation therapy (p < 0.05 compared to 
period 1). Compared to period 1, signiﬁ  cant differences were International Journal of COPD 2007:2(3) 395
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observed in the proportion of cases with the SZ phenotype 
and in pulmonary function measured by FEV1, which was 
found to be lower in period 1 (1.7 liters (SD = 1,1 L) versus 
2.1 L (SD = 1.2 L); p = 0.01.
Following the contacts established with the participat-
ing physicians the data of 130 (43%) out of the 301 patients 
included in period 1 were updated. The characteristics of 
both groups are shown in Table 2. No statistically signiﬁ  cant 
differences were observed between the initial updated data of 
the patients compared with those in whom new information 
could not be obtained.
A total of 462 different individuals were included in both 
periods. The sum of the patients included in period 2 plus 
those updated from period 1 provides a total of 291 patients 
with complete data as of January 2006 (Table 3). It is of note 
that 29% of the patients were not smokers and that 18% of 
the cases were detected on a family study. The percentage of 
subjects identiﬁ  ed through family screening increased from 
11% in period 1 to 21% in period 2. The mean FEV1 was 1.94 
L (SD = 1.2 L) and 33% were taking or had received augmenta-
tion therapy at the time of inclusion in the registry.
Discussion
Registries of patients with infrequent diseases are considered 
of great utility to improve the knowledge on their natural his-
tory and are an essential strategy to develop clinical studies 
with new therapies. This need has been demonstrated in the 
document by the WHO on AAT deﬁ  ciency in 1997 (WHO 
1997). The AIR was founded on the basis of this document 
by uniting the different existing national registries. Following 
its foundation, new countries have initiated their own national 
registry and have also become members thereby constituting 
Table 1 Characteristics of patients registered in the two registry 
periods: period 1 (1993–1999) and period 2 (2001–2005)
Characteristics  Period 1 (n = 301)  Period 2 (n = 161)
Sex, males (%)  69%  63%
Age, years (SD)  46 (13)  44 (16)
Active or ex-smoker (%)  46%  68%
Phenotype (%)
ZZ  284 (94%)  122 (76%)
SZ  4 (1.3%)  27 (17%)
Others  13 (4.3%)  7 (4.3%)
Augmentation therapy (%)  49%  12%
FEV1, L (SD)  1.7 (1.1)  2.1 (1.2)*
*p < 0.05 compared with period 1.
Table 2 Characteristics of the patients in period 1 according to 
the updating of the registry online
Characteristics Updated  (n = 130) Not  updated
     (n = 171)
Sex, males (%)  63%  74%
Age, Years (SD)  45 (14)  45 (15)
Smoker (active or ex)  76 (59%)  62 (36%)
Reason determination
Lung disease  92 (71%)  105 (61%)
Live disease  4 (3%)  1 (0.6%)
Family study  20 (15%)  12 (7%)
Not reported  14 (11%)  53 (31%)
Phenotype (%)
ZZ  122 (94%)  162 (95%)
SZ  1 (0.8%)  3 (2%)
Others  7 (5.4%)  2 (4%)
Augmentation therapy  49%  49%
FEV1, L (SD)  1.70 (1.1)  1.68 (1.1)
FEV1 % (SD)  54.7 (31.4)  53.2 (30.4)
Lung transplantation  3 (2%)  3 (2%)
p > 0.05 in all comparisons
Table 3 Characteristics of the patients in the Spanish Registry 
of AAT Deﬁ  ciency (n = 291). Includes those updated from period 
1 (n = 130) plus those newly registered in period 2 (n = 161)
Characteristics N = 291
Sex, males (%)  63.5%
Age, years (SD)  51 (14.9%)
Smokers
Non smoker  85 (29%)
Active smoker  26 (9%)
Ex-smoker 175  (60%)
Not reported  5 (1.7%)
Packs-year 26.5  (17.7)
Respiratory symptoms
Non productive cough  8 (3%)
Productive cough  41 (14%)
Resting dyspnea  10 (3.4%)
Effort dyspnea  144 (49%)
Dyspnea attacks  20 (7%)
No symptoms  68 (23%)
Reason for AAT determination
Lung disease  201 (59%)
Liver disease  22 (7.5%)
Family screening  53 (18%)
Population screening  1 (0.3%)
Others 10  (3.4%)
Not reported  4 (1.3%)
Phenotype
ZZ 247  (85%)
SZ 27  (9%)
Others 13  (4%)
Not reported  4 (1%)
Augmentation therapy  97 (33%)
FEV1, L (SD)  1.94 (1.2)
FVC, L (SD)  3.23 (1.2)
Transplantation
Lung 8  (3%)
Liver 2  (0.7%)International Journal of COPD 2007:2(3) 396
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the greatest registry of patients with AAT deficiency 
worldwide (Luisetti et al 2002).
To participate in the AIR the Spanish registry has had to 
adapt its questionnaire to the new format which includes a 
greater number of variables and has taken the opportunity to 
develop an application of on line data registry through the 
SEPAR website which allows any physician who diagnoses 
a case to include this information by computer. The data 
are encrypted and coded and are incorporated each semes-
ter in the AIR. The headquarters of the AIR database is in 
Malmo (Sweden) and currently includes more than 2,000 
patients from 21 countries. The questionnaire was initially 
made up of a document in the microsoft access format. 
Spain was the ﬁ  rst country to develop a questionnaire in the 
HTML format which could be ﬁ  lled out on line to thereby 
facilitate the participation of physicians throughout the 
country. This strategy has been useful to thereafter adapt 
the questionnaire to the national registries of Argentina and 
Brazil. The change in the structure of the registry which was 
necessary and was performed in 1999–2000 represented a 
loss of information since some physicians did not update 
the data of their patients registered previously with the 
paper questionnaire.
The other large registries of patients with AAT deﬁ  ciency 
are from the United States. The registry of the National 
Heart and Lung and Blood Institute (NHLBI) of the USA 
included 1,129 patients and had the objective of studying 
the natural history of the disease over ﬁ  ve years (McElvaney 
et al 1997). The registry was completed and the results have 
been published (The alpha-1-antitrypsin deﬁ  ciency registry 
study group 1998). The second is the Alpha One Foundation 
Research Network Registry (AOF-FNR) also from the USA 
and is based on patients who register themselves to be able to 
participate in studies and clinical trials. According to the data 
published, this registry included a total of 1,204 individuals 
in the year 2000 (Stoller et al 2000). Despite the differences 
between these registries, the characteristics of the patients 
included are similar in certain points: the disease was diag-
nosed in the 4th to 5th decade of life and males and index 
cases predominate over those detected in screening programs 
or family studies. In all the cases the delay in diagnosis and 
the low number of patients registered are constant compared 
to the reference population (Stoller et al 2005).
The initial population of the Spanish registry was also 
fundamentally made up of middle-aged males with a his-
tory of smoking and the ZZ phenotype in most cases as 
well as an important deterioration in respiratory function. 
The new cases are of similar age, although their pulmonary 
function is not as altered. The number of patients detected 
in family studies has also increased. These data are positive 
since they demonstrate a trend towards earlier diagnosis 
of the disease. This trend has not been observed in other 
countries such as the USA where there is a high diagnostic 
delay which has remained high during the last decades 
(Stoller et al 2005). It is therefore important to alert physi-
cians attending patients with COPD to the need for deter-
mining plasma concentrations of AAT in their patients at 
least once (ATS/ERS Statement 2003; Miravitlles 2004). 
Although the diagnosis of the deﬁ  ciency is not difﬁ  cult and 
its detection is a type A recommendation in the guidelines 
(ATS/ERS Statement 2003), all the studies undertaken have 
demonstrated that it is not performed early and underdiag-
nosis is a constant (ATS/ERS Statement 2003; Campos et al 
2005; Stoller et al 2005). The Spanish registry has carried 
out a screening campaign for the deﬁ  ciency in patients 
with COPD with the dried blood spots (Costa et al 2000; 
Rodriguez et al 2002) which has allowed the analysis of 
more than 2,000 samples and the diagnosis of 8 individuals 
with a severe deﬁ  ciency (De la Roza et al 2005; De la Roza 
et al 2006). Taking into account the expected number of 
patients with COPD in Spain (Sobradillo et al 2000), it can 
be said that there must be 5,000 patients with COPD due 
to a severe AAT deﬁ  ciency. These numbers are somewhat 
lower than the number of homozygote PiZZ individuals 
expected on epidemiological calculations derived from 
studies analyzing the genic frequency in the population 
(Blanco et al 2006). These differences are, in part, due to 
the penetration of the gene, that is, the variability in the 
development of COPD in homozygotic carriers according 
to different factors such as smoking or other genetic deter-
minants of risk (Rodriguez et al 2005) which condition the 
fact that not all the PiZZ individuals develop emphysema 
at a similar age or with a similar severity. Nonetheless, 
the most optimistic estimations suggest that the Spanish 
registry only includes 6% of the probably existent cases in 
Spain. In view of these results, the new SEPAR guidelines 
on treatment of AAT deﬁ  ciency insist on the need for 
performing the determination of seric AAT in all patients 
with COPD (Vidal et al 2006).
Throughout the history of the registry the age of diagnosis 
has remained at a mean of between 44 and 46 years, despite 
the inclusion of children, most of whom were relatives of 
index cases with pulmonary emphysema or who had liver 
disease, in period 2. The fact that the registry is organized 
and directed by SEPAR without active participation of 
pediatricians or gastroenterologists probably explains the International Journal of COPD 2007:2(3) 397
Spanish registry of AAT deﬁ  ciency
reason why the mean age did not decrease. Indeed, there is 
a greater number of patients with the SZ deﬁ  ciency due to 
their not being initially included in the registry and what is 
even more relevant is that the number of new cases receiving 
augmentation therapy has signiﬁ  cantly decreased from 49% 
in period 1 to 12% in period 2. The most probable cause for 
these differences is the scarce availability of treatment for 
the patients, especially from 1999 to 2003 (Horowitz 1996; 
Miravitlles et al 1999). It is possible that the current number 
of patients receiving augmentation therapy is higher than 
that reported in the questionnaires since some patients may 
have started treatment after having been registered as not 
being treated.
Of the 301 patients registered up to 1999, 170 were not 
included in the new database, despite the efforts to contact the 
physicians responsible for these cases. The reasons for this 
may be diverse. Some patients may have been lost to follow 
up on interrupting their visits to the physician or changing 
their physician. Deaths not reported to the registry may also 
be possible. On other occasions the physicians responsible 
could not be contacted because of a change in work place. 
Our results did not show any characteristic to differentiate 
updated from non updated patients, thereby suggesting that 
neither clinical nor demographic characteristics justify the 
lack of updating of some patients.
A total of 462 different patients have been registered 
during the time the registry has existed. Of these patients, 
the current database contains information on 291 individu-
als, 120 of whom were registered during the ﬁ  rst period and 
were later updated and 161 included in period 2. A total of 
171 patients were not newly registered after belonging to the 
initial registry. The most common proﬁ  le of the patients is a 
male smoker in whom the main symptoms include effort dys-
pnea and COPD, with a FEV1 of around 1.5 liters. The most 
frequent phenotype is the PiZ, although PiSZ heterozygotes 
are also currently registered. The cases of severe deﬁ  ciency 
by alleles other than Z and S are exceptional, with two new 
variants described in Spain being of note (Ybarcelona and 
Mvall d’hebron) (Jardi et al 2000; Miravitlles et al 2003). The 
inclusion of patients in the registry is the only valid strategy 
to know the characteristics of these patients and their needs 
in Spain as well as to participate in clinical studies aimed at 
establishing better treatment or even a cure for this genetic 
disease.
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